Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1224 Results

Title
Intervention Indication Therapeutic Area Year Actions
Pertuzumab biosimilar with trastuzumab and chemotherapy neoadjuvant and adjuvant therapy for early stage and locally advanced HER2-positive breast cancer Chemotherapy , Pertuzumab biosimilar , Trastuzumab (Herceptin; RG-597) Breast cancer Breast Cancer 2024 View  |  Download
Pevonedistat in addition to azacitidine for Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low Blast Acute Myeloid Leukemia – first-line Azacitidine (Vidaza; CC-486) , Pevonedistat (MLN-4924; TAK-924) Acute myeloid leukaemia (AML) , Chronic myelomonocytic leukaemia (CMML) , Myelodysplastic syndrome (MDS) Haematological Cancer and Lymphomas 2020 View  |  Download
Pexastimogene devacirepvec (pexa-vec) for hepatocellular carcinoma – first line Pexastimogene devacirepvec (Pexa-vec; JX-594) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2017 View  |  Download
Pexidartinib for tenosynovial giant cell tumour Pexidartinib (PLX3397) Tenosynovial giant cell tumour (TGCT) Oncology 2019 View  |  Download
Phelinun for reduced intensity conditioning treatment prior to allogeneic haematopoietic stem cell transplantation Melphalan hydrochloride (Cydex; CDX-353; Phelinun) Acute myeloid leukaemia (AML) , Hodgkin lymphoma , Multiple myeloma (MM) , Neuroblastoma , Non-Hodgkin lymphoma (NHL) , Ovarian cancer Female Reproductive Cancer , Haematological Cancer and Lymphomas , Neurological Cancer 2021 View  |  Download
Pioglitazone for sudden sensorineural hearing loss Pioglitazone (Actos; AD-4833; pioglitazone hydrochloride) Sudden sensorineural hearing loss Ear Nose and Throat (ENT) , Neurology 2019 View  |  Download
Pirtobrutinib for chronic lymphocytic leukaemia or small lymphocytic lymphoma after BTK inhibitor therapy Pirtobrutinib (LY3527727; LOXO-305) Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL) Haematological Cancer and Lymphomas 2023 View  |  Download
Pirtobrutinib for mantle cell lymphoma Pirtobrutinib (LY3527727; LOXO-305) Mantle cell lymphoma Haematological Cancer and Lymphomas 2021 View  |  Download
Pirtobrutinib for previously treated Bruton tyrosine kinase inhibitor naïve mantle cell lymphoma Pirtobrutinib (LY3527727; LOXO-305) Mantle cell lymphoma Haematological Cancer and Lymphomas 2024 View  |  Download
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma Pirtobrutinib (LY3527727; LOXO-305) Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL) Haematological Cancer and Lymphomas 2023 View  |  Download
1 2 85 86 87 88 89 122 123
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications